Rallybio (RLYB) Competitors

Artiva Biotherapeutics has a consensus price target of $39.00, suggesting a potential upside of 471.01%. Given Artiva Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Artiva Biotherapeutics is more favorable than Rallybio.

Rallybio has a beta of -0.72, suggesting that its stock price is 172% less volatile than the broader market. Comparatively, Artiva Biotherapeutics has a beta of 2.4, suggesting that its stock price is 140% more volatile than the broader market.

Rallybio has higher revenue and earnings than Artiva Biotherapeutics. Rallybio is trading at a lower price-to-earnings ratio than Artiva Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

In the previous week, Artiva Biotherapeutics had 7 more articles in the media than Rallybio. MarketBeat recorded 7 mentions for Artiva Biotherapeutics and 0 mentions for Rallybio. Rallybio's average media sentiment score of 0.00 equaled Artiva Biotherapeutics'average media sentiment score.

Artiva Biotherapeutics has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Rallybio's return on equity of -40.53% beat Artiva Biotherapeutics' return on equity.

90.3% of Rallybio shares are held by institutional investors. 10.3% of Rallybio shares are held by insiders. Comparatively, 1.8% of Artiva Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

52.2% of Benitec Biopharma shares are owned by institutional investors. Comparatively, 90.3% of Rallybio shares are owned by institutional investors. 4.8% of Benitec Biopharma shares are owned by insiders. Comparatively, 10.3% of Rallybio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Benitec Biopharma has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Benitec Biopharma's return on equity of -28.41% beat Rallybio's return on equity.

Rallybio has higher revenue and earnings than Benitec Biopharma. Benitec Biopharma is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks.

Benitec Biopharma has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market. Comparatively, Rallybio has a beta of -0.72, indicating that its stock price is 172% less volatile than the broader market.

In the previous week, Benitec Biopharma had 7 more articles in the media than Rallybio. MarketBeat recorded 7 mentions for Benitec Biopharma and 0 mentions for Rallybio. Rallybio's average media sentiment score of 0.00 beat Benitec Biopharma's score of -0.67 indicating that Rallybio is being referred to more favorably in the news media.

Benitec Biopharma presently has a consensus price target of $24.00, suggesting a potential upside of 167.26%. Given Benitec Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Benitec Biopharma is more favorable than Rallybio.

Rallybio has higher revenue and earnings than Eliem Therapeutics. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks.

In the previous week, Eliem Therapeutics' average media sentiment score of 0.00 equaled Rallybio'saverage media sentiment score.

Eliem Therapeutics has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Rallybio's return on equity of -40.53% beat Eliem Therapeutics' return on equity.

69.8% of Eliem Therapeutics shares are owned by institutional investors. Comparatively, 90.3% of Rallybio shares are owned by institutional investors. 4.7% of Eliem Therapeutics shares are owned by insiders. Comparatively, 10.3% of Rallybio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Eliem Therapeutics has a beta of -0.39, suggesting that its stock price is 139% less volatile than the broader market. Comparatively, Rallybio has a beta of -0.72, suggesting that its stock price is 172% less volatile than the broader market.

Emergent Biosolutions presently has a consensus price target of $10.00, suggesting a potential upside of 58.10%. Given Emergent Biosolutions' stronger consensus rating and higher probable upside, equities analysts clearly believe Emergent Biosolutions is more favorable than Rallybio.

In the previous week, Emergent Biosolutions had 2 more articles in the media than Rallybio. MarketBeat recorded 2 mentions for Emergent Biosolutions and 0 mentions for Rallybio. Emergent Biosolutions' average media sentiment score of 0.68 beat Rallybio's score of 0.00 indicating that Emergent Biosolutions is being referred to more favorably in the media.

78.4% of Emergent Biosolutions shares are held by institutional investors. Comparatively, 90.3% of Rallybio shares are held by institutional investors. 6.0% of Emergent Biosolutions shares are held by company insiders. Comparatively, 10.3% of Rallybio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Emergent Biosolutions has a net margin of -22.95% compared to Rallybio's net margin of -911.07%. Emergent Biosolutions' return on equity of 16.35% beat Rallybio's return on equity.

Emergent Biosolutions has a beta of 2.28, suggesting that its stock price is 128% more volatile than the broader market. Comparatively, Rallybio has a beta of -0.72, suggesting that its stock price is 172% less volatile than the broader market.

Emergent Biosolutions has higher revenue and earnings than Rallybio. Rallybio is trading at a lower price-to-earnings ratio than Emergent Biosolutions, indicating that it is currently the more affordable of the two stocks.